公開日期 | 標題 | 作者 | 來源出版物 | scopus | WOS | 全文 |
2020 | Nivolumab safety and efficacy in advanced, platinum-resistant, non-small cell lung cancer, radical radiotherapy-ineligible patients: A phase II study in Taiwan | Chen Y.-M.; CHIH-HSIN YANG ; Su W.-C.; Chong I.-W.; Hsia T.-C.; Lin M.-C.; Chang G.-C.; Chiu C.-H.; CHAO-CHI HO ; Wu S.-Y.; Hung J.-Y.; Wang C.-C.; Yang T.-Y.; CHONG-JEN YU | Journal of the Formosan Medical Association | 8 | 5 | |
2022 | An Observational Study on Treatment Outcomes in Patients With Stage III NSCLC in Taiwan: The KINDLE Study | Su P.-L.; Chang G.-C.; Hsiao S.-H.; Hsia T.-C.; Lin M.-C.; Lin M.-H.; JIN-YUAN SHIH ; Yang C.-T.; Yang S.-H.; Chen Y.-M. | JTO Clinical and Research Reports | 2 | 0 | |
2003 | Prediction of Survival in Surgical Unresectable Lung Cancer by Artificial Neural Networks Including Genetic Polymorphisms and Clinical Parameters | Hsia T.-C.; Chiang H.-C.; MING-HUANG CHIANG ; Hang L.-W.; Tsai F.-J.; Chen W.-C. | Journal of Clinical Laboratory Analysis | | | |
2017 | Predictive factors for EGFR-tyrosine kinase inhibitor retreatment in patients with EGFR-mutated non-small-cell lung cancer – A multicenter retrospective SEQUENCE study | Chang G.-C.; Tseng C.-H.; Hsu K.-H.; CHONG-JEN YU ; Yang C.-T.; Chen K.-C.; Yang T.-Y.; Tseng J.-S.; Liu C.-Y.; WEI-YU LIAO ; Hsia T.-C.; Tu C.-Y.; Lin M.-C.; Tsai Y.-H.; Hsieh M.-J.; Wu W.-S.; Chen Y.-M. | Lung Cancer | 22 | 18 | |
2019 | Ramucirumab plus erlotinib in patients with untreated, EGFR-mutated, advanced non-small-cell lung cancer (RELAY): a randomised, double-blind, placebo-controlled, phase 3 trial | Nakagawa K.; Garon E.B.; Seto T.; Nishio M.; Ponce Aix S.; Paz-Ares L.; Chiu C.-H.; Park K.; Novello S.; Nadal E.; Imamura F.; Yoh K.; JIN-YUAN SHIH ; Au K.H.; Moro-Sibilot D.; Enatsu S.; Zimmermann A.; Frimodt-Moller B.; Visseren-Grul C.; Reck M.; Chu Q.; Cortot A.; Pujol J.-L.; Fabre E.; Lamour C.; Bischoff H.; Kollmeier J.; Kimmich M.; Engel-Riedel W.; Hammerschmidt S.; Schütte W.; Syrigos K.; Ho J.C.M.; Au K.-H.; Ardizzoni A.; Pasello G.; Gregorc V.; Del Conte A.; Galetta D.; Takahashi T.; Kumagai T.; Hotta K.; Goto Y.; Hosomi Y.; Sakai H.; Takiguchi Y.; Kim Y.H.; Kurata T.; Yamaguchi H.; Daga H.; Okamoto I.; Satouchi M.; Ikeda S.; Kasahara K.; Atagi S.; Azuma K.; Aoe K.; Horio Y.; Yamamoto N.; Tanaka H.; Watanabe S.; Nogami N.; Ozaki T.; Koyama R.; Hirashima T.; Kaneda H.; Tomii K.; Fujita Y.; Seike M.; Nishimura N.; Kato T.; Ichiki M.; Saka H.; Hirano K.; Nakahara Y.; Sugawara S.; Kim S.-W.; Min Y.J.; Lee H.W.; Kang J.-H.; An H.J.; Lee K.H.; Kim J.-S.; Lee G.-W.; Lee S.Y.; Alexandru A.; Udrea A.A.; Juan-Vidal Ó.; Nadal-Alforja E.; Gil-Bazo I.; Ponce-Aix S.; Rubio-Viqueira B.; Alonso Garcia M.; Felip Font E.; Fuentes Pradera J.; Coves Sarto J.; Lin M.-C.; Su W.-C.; Hsia T.-C.; Chang G.-C.; Wei Y.-F.; Su J.; Cicin I.; Goksel T.; Harputluoglu H.; Ozyilkan O.; Henning I.; Popat S.; Hatcher O.; Mileham K.; Acoba J.; Garon E.; Jung G.; Raj M.; Martin W.; Dakhil S. | The Lancet Oncology | 410 | 341 | |
2007 | Revisit of 1997 TNM staging system - Survival analysis of 1112 lung cancer patients in Taiwan | Perng R.-P.; Chen C.-Y.; Chang G.-C.; Hsia T.-C.; Hsu N.-Y.; Tsai Y.-H.; Tsai C.-M.; CHIH-HSIN YANG ; Chen Y.-M.; CHONG-JEN YU ; Lee J.-J.; Hsu H.-S.; Yu C.-T.; Kao E.-L.; Chiu C.-H. | Japanese Journal of Clinical Oncology | 12 | 7 | |
2020 | Safety, Efficacy, and Pharmacokinetics of Almonertinib (HS-10296) in Pretreated Patients With EGFR-Mutated Advanced NSCLC: A Multicenter, Open-label, Phase 1 Trial | CHIH-HSIN YANG ; Camidge D.R.; Yang C.-T.; Zhou J.; Guo R.; Chiu C.-H.; Chang G.-C.; Shiah H.-S.; Chen Y.; Wang C.-C.; Berz D.; Su W.-C.; Yang N.; Wang Z.; Fang J.; Chen J.; Nikolinakos P.; Lu Y.; Pan H.; Maniam A.; Bazhenova L.; Shirai K.; Jahanzeb M.; Willis M.; Masood N.; Chowhan N.; Hsia T.-C.; Jian H.; Lu S. | Journal of Thoracic Oncology | 91 | 75 | |
2020 | Tepotinib plus gefitinib in patients with EGFR-mutant non-small-cell lung cancer with MET overexpression or MET amplification and acquired resistance to previous EGFR inhibitor (INSIGHT study): an open-label, phase 1b/2, multicentre, randomised trial | Wu Y.-L.; Cheng Y.; Zhou J.; Lu S.; Zhang Y.; Zhao J.; Kim D.-W.; Soo R.A.; Kim S.-W.; Pan H.; Chen Y.-M.; Chian C.-F.; Liu X.; Tan D.S.W.; Bruns R.; Straub J.; Johne A.; Scheele J.; Park K.; CHIH-HSIN YANG ; Liu Z.; Chen X.; Wang M.; Yu S.; Zhang H.; Fang J.; Li W.; Yang C.-H.; Chang G.-C.; Hsia T.-C.; Yang C.-T.; Wang C.-C.; Cho B.C.; Lee K.H.; Kim Y.-C.; An H.J.; Woo I.S.; Cho J.Y.; Shin S.W.; Lee J.-S.; Kim J.-H.; Yoo S.S.; Kato T.; Shinagawa N.; Tan S.W.D.; Ngo L.S.-M.; Ratnavelu K.; Ahmad A.R.; Liam C.K.; de Marinis F.; Tassone P.; Molla A.I.; Calles Blanco A.; Lazaro Quintela M.E.; Felip Font E.; Dingemans A.-M.; Bui L. | The Lancet Respiratory Medicine | 170 | 128 | |
2022 | Tyrosine Kinase Inhibitor Activity in Patients with NSCLC Harboring Uncommon EGFR Mutations: A Retrospective International Cohort Study (UpSwinG) | Popat S.; Hsia T.-C.; Hung J.-Y.; Jung H.A.; JIN-YUAN SHIH ; Park C.K.; Lee S.H.; Okamoto T.; Ahn H.K.; Lee Y.C.; Sato Y.; Lee S.S.; Mascaux C.; Daoud H.; Märten A.; Miura S. | The oncologist | 14 | 9 | |
2007 | Urinary biomarker of oxidative stress correlating with outcome in critically septic patients | Cheng W.-E.; Shih C.-M.; Hang L.-W.; KUEN-YUH WU ; Yang H.-L.; Hsu W.-H.; Hsia T.-C. | Intensive Care Medicine | 10 | 11 | |
2007 | Urinary biomarker of oxidative stress correlating with outcome in critically septic patients | Hsia T.-C.; Cheng W.-E.; Shih C.-M.; Hang L.-W.; KUEN-YUH WU ; Yang H.-L.; Hsu W.-H. | Intensive Care Medicine | 8 | 6 | |